EANM’08 – CME Session V
October 13, 2008, 08:00 – 09:30
PET/CT in Prostate Cancer: is there a Clinical Value?
Moderator: A. Chiti (Milan)
Co-Moderator: A.-L. Grosu (Freiburg)
|A.-L. Grosu (Freiburg):
When and Why a Patient with Prostate Cancer needs a PET/CT Scan
|M. Picchio (Milan):
Experience with 11C-Methylcholine
|J.N. Talbot (Paris):
Experience with 18F-Fluoromethylcholine
- Identify the correct clinical indications for PET/CT in prostate cancer.
- Know the different characteristics and limitations of carbon-11 and fluoro-18 labeled choline.
- Recognize the most common patterns of pathological uptake of choline in prostate cancer.
The session is directed towards nuclear physicians experienced with PET/CT in oncology but with little or no experience in the use of this technique in prostate cancer.
After a clinical introduction on the usefulness and limits of choline PET from the radiation therapist point of view, two qualified nuclear medicine physician will describe their experience.
Since there are two main radiopharmaceuticals already used for these studies, labeled with carbon-11 and fluorine-18, the speakers will describe their clinical experience and also the different characteristics of the two radiopharmaceuticals, with a particular emphasis on the physiological and pathological biodistribution of 11C and 18F labeled choline.
Prostate cancer, PET, choline